Financhill
Sell
37

NKTX Quote, Financials, Valuation and Earnings

Last price:
$1.81
Seasonality move :
41.73%
Day range:
$1.79 - $1.88
52-week range:
$1.31 - $2.74
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.38x
Volume:
887K
Avg. volume:
815.5K
1-year change:
-31.82%
Market cap:
$127.9M
Revenue:
--
EPS (TTM):
-$1.39

Analysts' Opinion

  • Consensus Rating
    Nkarta, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 1 Hold rating, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $11.25, Nkarta, Inc. has an estimated upside of 525% from its current price of $1.80.
  • Price Target Downside
    According to analysts, the lowest downside price target is $8.00 representing 100% downside risk from its current price of $1.80.

Fair Value

  • According to the consensus of 5 analysts, Nkarta, Inc. has 525% upside to fair value with a price target of $11.25 per share.

NKTX vs. S&P 500

  • Over the past 5 trading days, Nkarta, Inc. has underperformed the S&P 500 by -5.06% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Nkarta, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Nkarta, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Nkarta, Inc. reported revenues of --.

Earnings Growth

  • Nkarta, Inc. has grown year-over-year earnings for 9 quarters straight. In the most recent quarter Nkarta, Inc. reported earnings per share of -$0.29.
Enterprise value:
-77.8M
EV / Invested capital:
-0.19x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.83x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$9.2M
Return On Assets:
-21.56%
Net Income Margin (TTM):
--
Return On Equity:
-26.82%
Return On Invested Capital:
-22.18%
Operating Margin:
--
Trailing 12 Months Fiscal Quarters
Period Ending 2023-09-30 2024-09-30 2025-09-30 2024-09-30 2025-09-30
Income Statement
Revenue -- -- -- -- --
Gross Profit -$6.7M -$9.1M -$9.2M -$2.3M -$2.3M
Operating Income -$135.4M -$128.5M -$122M -$33.8M -$27.3M
EBITDA -$128.8M -$119.3M -$112.7M -$31.4M -$25M
Diluted EPS -$2.50 -$1.87 -$1.39 -$0.39 -$0.29
Period Ending 2021-09-30 2022-09-30 2023-09-30 2024-09-30 2025-09-30
Balance Sheet
Current Assets $264.6M $400.9M $281.2M $290.2M $289.3M
Total Assets $292.5M $503.8M $405.9M $532M $427.2M
Current Liabilities $12.1M $26.4M $25.6M $22.5M $19M
Total Liabilities $22.5M $104.5M $109M $101.2M $89.3M
Total Equity $270M $399.3M $296.8M $430.9M $337.9M
Total Debt $10.3M $78.1M $83.4M $78.7M $70.3M
Trailing 12 Months Fiscal Quarters
Period Ending 2023-09-30 2024-09-30 2025-09-30 2024-09-30 2025-09-30
Cash Flow Statement
Cash Flow Operations -$70.1M -$98.3M -$91.8M -$24.5M -$18.7M
Cash From Investing $67.9M -$109.2M $94.7M -$38.9M $25.4M
Cash From Financing $820K $226.2M $261K $2K --
Free Cash Flow -$126.5M -$108.4M -$93.6M -$25.3M -$18.7M
NKTX
Sector
Market Cap
$127.9M
$28.5M
Price % of 52-Week High
65.69%
51.44%
Dividend Yield
0%
0%
Shareholder Yield
1.04%
-1.33%
1-Year Price Total Return
-31.82%
-20.32%
Beta (5-Year)
0.799
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

Technicals

8-day SMA
Sell
Level $1.81
200-day SMA
Sell
Level $1.94
Bollinger Bands (100)
Sell
Level 1.91 - 2.27
Chaikin Money Flow
Buy
Level 110.9M
20-day SMA
Sell
Level $1.84
Relative Strength Index (RSI14)
Sell
Level 42.56
ADX Line
Sell
Level 18.68
Williams %R
Neutral
Level -56.5217
50-day SMA
Sell
Level $2.06
MACD (12, 26)
Sell
Level -0.07
25-day Aroon Oscillator
Sell
Level -60
On Balance Volume
Neutral
Level 177.1M

Financial Scores

Sell
Altman Z-Score (Annual)
Level (-0.623)
Sell
CA Score (Annual)
Level (-0.5208)
--
Beneish M-Score (Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (0.9132)
--
Piotroski F Score (Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The firm’s product include NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes, and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.

Stock Forecast FAQ

In the current month, NKTX has received 4 Buy ratings 1 Hold ratings, and 0 Sell ratings. The NKTX average analyst price target in the past 3 months is $11.25.

  • Where Will Nkarta, Inc. Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Nkarta, Inc. share price will rise to $11.25 per share over the next 12 months.

  • What Do Analysts Say About Nkarta, Inc.?

    Analysts are divided on their view about Nkarta, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Nkarta, Inc. is a Sell and believe this share price will drop from its current level to $8.00.

  • What Is Nkarta, Inc.'s Price Target?

    The price target for Nkarta, Inc. over the next 1-year time period is forecast to be $11.25 according to 5 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.

  • Is NKTX A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Nkarta, Inc. is a Buy. 4 of 5 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of NKTX?

    You can purchase shares of Nkarta, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Nkarta, Inc. shares.

  • What Is The Nkarta, Inc. Share Price Today?

    Nkarta, Inc. was last trading at $1.81 per share. This represents the most recent stock quote for Nkarta, Inc.. Yesterday, Nkarta, Inc. closed at $1.80 per share.

  • How To Buy Nkarta, Inc. Stock Online?

    In order to purchase Nkarta, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Did SoFi Stock Drop?
Why Did SoFi Stock Drop?

Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…

Will Robinhood Win AI Investing?
Will Robinhood Win AI Investing?

Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…

Is Amazon an AI Stock?
Is Amazon an AI Stock?

With the market starting to look skittish on pure-play AI…

Stock Ideas

Buy
52
Is NVDA Stock a Buy?

Market Cap: $4.4T
P/E Ratio: 62x

Buy
56
Is AAPL Stock a Buy?

Market Cap: $4.1T
P/E Ratio: 37x

Buy
81
Is GOOG Stock a Buy?

Market Cap: $3.9T
P/E Ratio: 40x

Alerts

Sell
50
TGL alert for Dec 8

Treasure Global, Inc. [TGL] is up 31.68% over the past day.

Buy
56
SMX alert for Dec 8

SMX (Security Matters) Plc [SMX] is down 45.78% over the past day.

Buy
62
PRAX alert for Dec 8

Praxis Precision Medicines, Inc. [PRAX] is up 8.15% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock